Thanh H. Dellinger, M.D.

[email protected]
(877) 460-4673
Thanh H. Dellinger, M.D.
Gynecologic Oncologist
Clinical Expertise
  • Ovarian Cancer
  • Uterine Cancer
  • Cervical Cancer
  • PIPAC — Pressurized Intraperitoneal Aerosol Chemotherapy
  • HIPEC — Hyperthermic (or Heated) Intraperitoneal Chemotherapy
  • Fertility Sparing Cancer Treatments
  • Vulvar Cancer
  • Vaginal Cancer
Research Area
  • Uterine/Endometrial Cancer
  • Novel Therapies in Ovarian Cancer
  • Hyperthermic Intraperitoneal Cancer
  • PIPAC
Other Languages Spoken
Chaozhou
German
Academic Appointments
  • Associate Professor, Division of Gynecologic Oncology, Department of Surgery
Clinical Teams
Cervical Cancer
HIPEC — Hyperthermic (or Heated) Intraperitoneal Chemotherapy
PIPAC — Pressurized Intraperitoneal Aerosol Chemotherapy
Surgery — Gynecological Oncology
Additional Contacts
  • Glendora Patients
    (626) 914-3921
  • Referring Physicians/Colleagues
    (626) 218-3505

Thanh Dellinger, M.D., is a gynecologic oncologist with specialized training in robotic-assisted (minimally invasive) surgery for uterine and cervical cancer, which can be as effective as traditional surgery but with reduced scarring, pain and recovery time.

Dr. Dellinger is also an expert in advanced cytoreductive surgery for ovarian cancer, which can significantly improve survival outcomes for patients. Additionally, Dr. Dellinger has specialized training in PIPAC, a novel drug delivery method for recurrent ovarian cancer patients, and currently leads the first in U.S. clinical trial evaluating this novel therapy (NCT04329494.)

Dr. Dellinger’s research focus is in ovarian and uterine cancer, and she has co-authored over fifty papers on HIPEC, PIPAC, and novel therapies and molecular pathways in ovarian and uterine cancer. Her current clinical research focuses on optimizing PIPAC and HIPEC in ovarian cancer patients.

Dr. Dellinger received her medical degree at University of California Irvine, followed by a residency at Penn State University and a gynecologic oncology fellowship at University of California Irvine Medical Center.

Location

Education & Experience

Board Certifications

  • 2014-2022, Diplomate of the American Board of Obstetrics and Gynecology

Degrees

  • 2004, M.D., University of California Irvine School of Medicine, Irvine, CA

  • 1999, B.S., Biochemistry/Chemistry, University of California San Diego, La Jolla, CA

Fellowship

  • 2010-2012, Clinical Fellowship in Gynecological Oncology, UCI Medical Center, University of California Irvine, Orange, CA

  • 2008-2010, Research Fellowship in Gynecological Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA

Residency

  • 2004-2008, Residency, Obstetrics & Gynecology, Penn State University, Milton S. Hershey Medical Center, Hershey, PA

Professional Experience

  • 2020-present, Associate Professor, Division of Gynecologic Oncology, Department of Surgery, City of Hope, Duarte, CA

  • 2012-2020, Assistant Professor, Division of Gynecologic Oncology, Department of Surgery, City of Hope, Duarte, CA

  • 2008- 2012, Clinical Instructor, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Irvine, CA

Awards & Memberships

Awards

  • 2020-present, Top Doctor, Los Angeles

  • 2016-2018, Top Doctor, Pasadena Magazine

  • 2020, Oxnard Foundation Grand Award

  • 2013-2018, Pasadena Magazine Top Doctors

Memberships

  • 2022-present, Society of Surgical Oncology (SSO)

  • 2021-present, International Society for Study of Pleura and Peritoneum (ISSPP)

  • 2021-2022, 3rd ISSPP Congress, Co-Chair of Planning committee

  • 2016-present, Active Member, International Gynecologic Cancer Society

  • 2014-present, Active Member, NRG Oncology

  • 2014-present, Fellow, American College of Obstetricians and Gynecologists (ACOG)

  • 2009-present, Active Member, American Society of Clinical Oncology (ASCO)

  • 2008-present, Active Member, Society of Gynecologic Oncologists (SGO)

  • 2008-present, Active Member, American Association of Cancer Research (AACR)

  • 2008-present, Active Member, Gynecologic Oncology Group (GOG)

Publications

  • Mustafa Raoof, Kevin M. Sullivan, Paul H. Frankel, Marwan Fakih, Timothy W. Synold, Dean Lim, Yanghee Woo, Isaac Benjamin Paz, Yuman Fong, Rebecca Meera Thomas, Sue Chang, Melissa Eng, Raechelle Tinsley, Richard L. Whelan, Danielle Deperalta, Marc A. Reymond, Jeremy Jones, Amit Merchea and Dellinger TH, Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design, Pleura and Peritoneum 2022; aop, doi.org/10.1515/pp-2022-0116, published online June 21, 2022, PMID 36560966
  • Adamson AW, Ding YC, Steele L, Leong LA, Morgan R, Wakabayashi MT, Han ES, Dellinger TH, Lin PS, Hakim AA, Wilczynski S, Warden CD, Tao S, Bedell V, Cristea MC, Neuhausen SL. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer. Res Sq [Preprint]. 2023 Feb 20:rs.3.rs-2592107. doi: 10.21203/rs.3.rs-2592107/v1. PMID: 36865331; PMCID: PMC9980206.
  • Rosemary Noel Senguttuvan, Christina Wei, Mustafa Raoof, Dellinger TH, Edward Wenge Wang, Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma, J Clin Med. 2023 Jun 4;12(11):3839. doi:10.3390/jcm12113839. PMID 37298034
  • Kohut, A., Whitaker, T., Walter, L., Li, S. Y., Han, E., Lee, S., Wakabayashi, M. T., Dellinger TH., Han, E. S., Rodriguez-Rodriguez, L. R., & Chung, C. (2022). Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgery. International Urogynecology Journal. 2022 May DOI:10.1007/s00192-022-05212-7. PMID 35501570
  • Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He T, Lee P, Razavi M, Liang W, Schmolze D, Priceman S, Lee S, Lin W, Lin J, Kebria M, Hakim A, Ruel N, Stewart D, Wang E, Paz B, Wakabayashi MT, Cristea MC, Rodriguez-Rodriguez L. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) induced molecular changes in humans validate preclinical data in ovarian cancer. JCO Precision Oncology, JCO Precis Oncol. 2022 Mar;6:e2100239. doi: 10.1200/PO.21.00239. PMID 35357903
  • Sgarbura O, Eveno C, Alyami M, Bakrin N, Guiral D, Ceelen W, Delgadillo X, Dellinger TH, Kefleyesus A, Khomiakov V, Bau Mortensen M, Murphy J, Pocard M, Reymond M, Robella M, Rovers K, So J, Somashekhar SP, Tempfer C, Van Der Speeten K, Villeneuve L, Yong WP, Huebner M. Consensus statement for treatment protocols for pressurized intraperitoneal aerosol chemotherapy (PIPAC), Pleura & Peritoneum, 2022 Mar 1;7(1):1-7. doi: 10.1515/pp-2022-0102. PMID 35602919
  • Colton Ladbury, Richard Li, Jay Shiao, Jason Liu, Mihaela Cristea, E Han, Dellinger TH, Stephen Lee, Edward Wang, Christine Fisher, Yi-Jen Chen, Arya Amini, Tyler Robin, Scott Glaser. Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging?, Gynecol Oncol. 2022 Jan;164(1):39-45. doi:10.1016/j.ygyno.2021.11.007. Epub 2021 Nov 15. PMID 34794840
  • Raoof M, Malhotra G, Kohut A, O'Leary M, Frankel P, Tran T, Fakih M, Chao J, Lim D, Woo Y, Paz IB, Lew M, Cristea MC, Rodriguez-Rodriguez L, Fong Y, Blakely A, Whelan R, Reymond MA, Merchea A, Dellinger TH. PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Ann Surg Oncol. 2021 Aug 13. doi:10.1245/s10434-021-10505-0. Epub ahead of print. PMID: 34387765.
  • Raoof M, Dellinger TH, ASO Author Reflections: Defining the Role of PIPAC in the Treatment of Peritoneal Metastases, Ann Surg Oncol. 2021 Jul 26. Doi: 10.1245/s10434-021-10548-3. PMID 343127996
  • Chung CP, Edrosa E, Wakabayashi MT, Dellinger TH, Lee SJ, Chan K, Han ES. Prolapse repair after anterior exenteration. Int Urogynecol J. 2021 Apr;32(4):1037-1038. doi: 10.1007/s00192-020-04465-4. Epub 2020 Jul 31. PMID: 32737535.
  • Mooney R, Wafa Abidi, Jennifer Batalla-Covello, Hoi Wa Ngai, Caitlyn Hyde, Diana Machado, Asma Abdul-Majid, Yanan Kang, Mohamed Hammad, Linda Flores, Greg Copeland, Dellinger TH, Han ES, Jacob Berlin, Karen S Aboody, Allogeneic human neural stem for improved therapeutic delivery to peritoneal ovarian cancer. Stem Cell Res Ther. 2021 Mar 24;12(1):205. doi: 10.1186/s13287-021-02226-8
  • Stewart C, Raoof M, Yuman Fong, Dellinger TH, Warner S Who Is Hurting? A Prospective Study of Surgeon Ergonomics Pacific Coast Surgical Association (PCSA) 91st Annual Meeting. Surg Endosc. 2021 Feb 1. doi:10.1007/s00464-020-08274-0. Epub ahead of print. PMID: 33523280
  • Cornejo Y, Li M, Dellinger TH, Mooney R, Rahman MM, McFadden G, Aboody KS, Hammad M. NSCs are permissive to oncolytic Myxoma virus and provide a delivery method for targeted ovarian cancer therapy. Oncotarget. 2020 Dec 22;11(51):4693-4698. doi: 10.18632/oncotarget.27845. PMID:33473255; PMCID: PMC7771716.
  • Mohamed Hammad, Yvonne Cornejo, Linda Flores, Caitlyn Hyde, Hoi Wa Ngai, Min Li, Dellinger TH, Jianming Lu, Nanhai G Chen, Rachael Mooney, Karen S Aboody, Yuman Fong. Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis. Mol Ther Oncolytics. 2020 Oct:19:278-282. PMID: 33251335
  • Dellinger TH, Ernest S. Han, State of the Science: The role of HIPEC in the treatment of ovarian cancer. Gynecol Oncol. 2021. 2021 Jan 5; S0090-8258(20)34243-8. PMID: 33419611
  • Wei Wen, Ernest S. Han, Dellinger TH, Leander Lu, Jun Wu, Richard Jove, John H. Yim, Synergistic anti-tumor activity by targeting multiple signaling pathways in ovarian cancer. Cancers (Basel). 2020 Sep 10;12(9):2586. doi: 10.3390/cancers12092586. PMID: 32927828
  • Haber T, Cornejo YR, Aramburo S, Flores L, Cao P, Liu A, Mooney R, Gilchrist M, Tirughana R, Nwokafor U, Abidi W, Han E, Dellinger TH, Wakabayashi MT, Aboody KS, Berlin JM. Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles. Proc Natl Acad Sci USA. 2020 Aug 18;117(33):19737-19745. doi: 10.1073/pnas.1917424117. Epub 2020 Jul 30. PMID: 32732430
  • Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger TH, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez L. Frontline management of epithelial ovarian cancer — combining clinical expertise with community practice collaboration and cutting-edge research. Journal of Clinical Medicine, Received: 21 July 2020. PMID 32882942
  • C Chung, E Edrosa, M Wakabayash, S Lee, Dellinger TH, K Chan, E Han “Prolapse Repair After Anterior Exenteration” Int Urogynecol J. 2020 July; D-20-00273R1. PMID 32737535
  • Hammad M, Cornejo YR, Batalla-Covello J, Abdul Majid A, Burke C, Liu Z, Yuan Y-C, Li M, Dellinger TH, Lu J, Chen NG, Fong Y, Aboody KS, Mooney R, Neural Stem Cells Improve the Delivery of Oncolytic Chimeric Orthopoxvirus in a Metastatic Ovarian Cancer Model, Molecular Therapy: Oncolytics (2020), doi: https://doi.org/10.1016/j.omto.2020.07.002. PMID 32775617
  • Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzaga J, Tirughana R, Hammad M, Dellinger TH, Lesniak MS, Curiel DT, Aboody KS. Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer. Mol Ther Oncolytics. 2020 Jun 11;17:508. doi: 10.1016/j.omto.2020.05.005. eCollection 2020 Jun 26. PMID: 32577499
  • Wen W, Han ES, Dellinger TH, Wu J, Guo Y, Buettner R, Horne D, Jove R, Yim J. Increasing anti-tumor activity of JAK inhibitor by simultaneous blocking multiple survival signaling pathways in human ovarian cancer. Translational Oncology. 2019 Aug 12;12(8):1015-1025. doi: PMID 31141756
  • Tiet P, Li J, Abidi W, Mooney R, Flores L, Aramburo S, Batalla-Covello J, Gonzaga J, Tsaturyan L, Kang Y, Cornejo Y, Dellinger TH, Han E, Aboody K, Berlin J. Silica Coated Paclitaxel Nanocrystals Enable Neural Stem Cell Loading For Treatment of Ovarian Cancer. Bioconjugate Chemistry. Bioconjug Chem. 2019 Apr 12. doi: 10.1021/acs.bioconjchem.9b00160. PMID:30835443
  • Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, Dellinger T, Park M, Morgan RJ. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol. 2019 Jan 8. doi: 10.1007/s00280-019-03767-9. PMID: 30623229
  • Shinde A, Li R, Amini A, Chen Y, Cristea M, Dellinger T, Wang W, Wakabayashi M, Beriwal S, Glaser S. Improved Survival with Adjuvant Brachytherapy in Stage IA Endometrial Cancer of Unfavorable Histology. Gynecol Oncol, 2018 Oct;151(1):82-90. doi: 10.1016/j.ygyno.2018.08.028. Epub 2018 Aug 28. PMID: 30170976
  • Chung C, Dao N, Wakabayashi M, Dellinger TH, Lee S, Han ES. Concurrent pelvic reconstruction and minimally invasive pelvic cancer surgery. Int Urogynecol J. 2018 Nov;29(11):1709-1711. doi:10.1007/s00192-018-3751-y. Epub 2018 Aug 18. PMID: 30121701
  • Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH. Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway. Int J Mol Sci. 2018 Jul 7;19(7). pii: E1983. doi:10.3390/ijms19071983. PubMed PMID: 29986501
  • Li R, Shinde A, Chen YJ, Amini A, Lee S, Dellinger T, Han E, Wakabayashi M, Nelson R, Beriwal S, Glaser S. Survival benefit of adjuvant brachytherapy after hysterectomy with positive surgical margins in cervical cancer. Int J Radiat Oncol Biol Phys. 2018 Jun 8. pii: S0360-3016(18)30929-5. doi:10.1016/j.ijrobp.2018.05.076. PubMed PMID: 29890264.
  • Dellinger TH, Smith DS, Ballard E, Wakabayashi M, Han ES. HIPEC treatment in advanced and recurrent ovarian cancer: A meta-analysis of observational studies. Eur J Gynaecol Oncol. 2018, June; 39(3):353-360
  • Han ES, Wen W, Dellinger TH, Wu J, Lu S, Jove R, Yim J. Ruxolitinib synergistically enhances the antitumor activity of paclitaxel in human ovarian cancer. Oncotarget, 2018 Jan 31;9(36):24304-24319. doi: 10.18632/oncotarget.24368. eCollection 2018 May 11. PubMed PMID: 29849942
  • Eng OS, Raoof M, Blakely AM, Yu X, Lee SJ, Han ES, Wakabayashi MT, Yuh B, Lee BY, Dellinger TH. A Collaborative Surgical Approach to Upper and Lower Abdominal Cytoreductive Surgery in Ovarian Cancer. J Surg Oncol. 2018. Jun 7. doi: 10.1002/jso.25120. [Epub ahead of print] PubMed PMID:29878375.
  • Chen SF, Liu Z, Chaurasiya S, Dellinger TH, Lu J, Wu X, Qin H, Wang J, Fong Y, Yuan YC. Identification of core aberrantly expressed microRNAs in serous ovarian carcinoma. Oncotarget. 2018 Apr 17;9(29):20451-20466. doi: 10.18632/oncotarget.24942. eCollection 2018 Apr 17. PubMed PMID:29755664.
  • Shahin SA, Wang R, Simargi SI, Contreras A, Parra L, Qu L, Wen W, Dellinger TH, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine. 2018 Apr 14. PMID: 29665439.
  • Chang H, Armenian S, Dellinger TH. Secondary neoplasms of the female lower genital tract after hematopoietic cell transplantation. JNCCN 2018 Feb 1. PMID: 29439180
  • Dumitra S, O’Leary M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Lee B. The Comprehensive Complication Index: A New Measure of the Burden of Complications after Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2017 Dec 19. PMID: 29260417
  • Eng OS, Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Paz IB, Lee B. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. JAMA Surg. 2017 Dec 1;152(12):1156-1160. PMID: 28832866.
  • Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH. Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer. Sci Rep. 7, Oct. 6, 2017. doi:10.1038/s41598-017-12922-2. PMID: 28986550
  • Cao P, Mooney R, Tirughana-Sambandan R, Abidi W, Aramburo S, Flores L, Gilchrist M, Nwokafor U, Tiet P, Annala A, Han E, Dellinger TH, Aboody K, Berlin JM. Intraperitoneal Administration of Neural Stem Cell Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjugate Chemistry, 2017 Jun 21;28(6):1767-1776. PMID: 28453256
  • Eng OS, Dumitra S, O’Leary M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Paz B, Singh G, Lee B. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol, 2017. Sep;24(9):2707-2711. PMID: 28560593
  • Roberts CM, Shahin SA, Loeza J, Dellinger TH, Williams JC, Glackin CA. Disruption of TWIST1-RELA binding by mutation and competitive inhibition to validate the TWIST WR domain as a therapeutic target. BMC Cancer, 2017 Mar 10;17(1):184. PMID: 28283022
  • Dellinger TH, Hakim AS, Lee S, Wakabayashi M, Morgan RM, Han ES. Surgical management of vulvar cancer. J Natl Compr Canc Netw. 2017 Jan;15(1):121-128. PMID: 28040722
  • Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine. 2016 Nov 24. pii: S1549-9634(16)30202-7. PMID: 27890656
  • Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, Mor G, Glackin CA. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signaling. Sci Rep. 2016 Nov 23; 6:37652. PMID: 27876874
  • Dellinger TH, Wakabayashi MT, Han ES. Comprehensive Staging of Uterine Carcinosarcoma Using a Multiquadrant Robotic Platform. J Minim Invasive Gynecol. 2016 Oct 26. pii: S1553-4650(16)31152-9. PMID: 27794476
  • Zhang K, Han ES, Dellinger TH, Lu J, Nam S, Anderson RA, Yim JH, Wen W. Cinnamon extract reduces VEGF expression via suppressing HIF-1α gene expression and inhibits tumor growth in mice. Mol Carcinog. 2016 Jun 2. PMID: 27253180
  • Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). Gynecol Oncol. 2016 May;141(2):336-40. PMID: 26861585
  • Eskander RN, Ali SM, Dellinger TH, Lankes HA, Randall LM, Ramirez NC; Monk BJ, Walker JL, Eisenhauer E, Hoang BH. Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study. International Journal of Gynecological Cancer, January 2016 - Volume 26 - Issue 1 - p 125–132. PMID: 26397159
  • Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh M, Horne D, Dellinger TH, Han ES, Jove R, Yim JH. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Molecular Cancer, 14:100 (01 May 2015)
  • Wen W, Liang W, Wu J, Kowolik C, Buettner R, Scuto A, Hsieh M, Hong H, Brown C, Forman S, Horne D, Morgan R, Wakabayashi M, Dellinger TH, Han E, Yim J, Jove R. (2014). Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 2014 Oct 15
  • Yang C, Lee H, Jove V, Deng J, Zhang W, Liu X, Forman S, Dellinger TH, Wakabayashi M, Yu H, Pal S. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLOS One, 2013;8(1):e54029.Epub 2013 Jan.10
  • Dellinger TH, Planutis K, Jandial D, Eskander RN, Zi X, Monk BJ, Martinez M, Holcombe RF. Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer. Gynecologic Oncology, 2012 Aug; 126(2):259-67.
  • Dellinger TH, Planutis K, Tewari KS, Holcombe RF. The Role of Canonical Wnt signaling in Endometrial Carcinogenesis. Expert Reviews of Anticancer Therapy, January 2012, 12(1):51-62.
  • Dellinger TH, Monk BJ. Systemic Therapy for Recurrent Endometrial Cancer: a review of North American trials. Expert Reviews of Anticancer Therapy 2009 Jul; 9(7):905-16.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Show respect for what you say
4.8
Know important info medical history
4.8
Spend enough time with you
4.8
Rate provider 0-10
02/03/25
You should offer the choice "outstanding". I have never received the level of service that Coty of Hope provided. I have no words to describe the entire experience. From the first phone call..Flawless, absolutely Incredible. - Verified patient
02/02/25
Fabulous doctor! - Verified patient
01/19/25
This was my first time meeting Dr. Dellinger. She explained everything to me clearly and patiently answered all of my questions. - Verified patient
01/19/25
Staff was excellent. I would recommend the office and provider to others. - Verified patient
01/03/25
There is no were else I would recommend so that's why I tell people how well they will be taken care of at none other than the city of hope - Verified patient